ATE197454T1 - Isoxazol- und isothiazolverbindungen, die die kognitiven funktionen verbesseren - Google Patents
Isoxazol- und isothiazolverbindungen, die die kognitiven funktionen verbesserenInfo
- Publication number
- ATE197454T1 ATE197454T1 AT92912971T AT92912971T ATE197454T1 AT E197454 T1 ATE197454 T1 AT E197454T1 AT 92912971 T AT92912971 T AT 92912971T AT 92912971 T AT92912971 T AT 92912971T AT E197454 T1 ATE197454 T1 AT E197454T1
- Authority
- AT
- Austria
- Prior art keywords
- isoxazole
- cognitive functions
- improve cognitive
- treatment
- isothiazole compounds
- Prior art date
Links
- 230000003920 cognitive function Effects 0.000 title 1
- 150000003854 isothiazoles Chemical class 0.000 title 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 title 1
- OLROCKKMZHTZFM-UHFFFAOYSA-N 1,2-oxazole;1,2-thiazole Chemical compound C=1C=NOC=1.C=1C=NSC=1 OLROCKKMZHTZFM-UHFFFAOYSA-N 0.000 abstract 1
- 206010001605 Alcohol poisoning Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 1
- 208000003554 absence epilepsy Diseases 0.000 abstract 1
- 230000001713 cholinergic effect Effects 0.000 abstract 1
- 230000006949 cholinergic function Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003217 pyrazoles Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70692091A | 1991-05-29 | 1991-05-29 | |
| PCT/US1992/004631 WO1992021339A1 (en) | 1991-05-29 | 1992-05-28 | Isoxazole and isothiazole compounds that enhance cognitive function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE197454T1 true ATE197454T1 (de) | 2000-11-11 |
Family
ID=24839628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92912971T ATE197454T1 (de) | 1991-05-29 | 1992-05-28 | Isoxazol- und isothiazolverbindungen, die die kognitiven funktionen verbesseren |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5409946A (de) |
| EP (1) | EP0588917B1 (de) |
| JP (1) | JP3153551B2 (de) |
| AT (1) | ATE197454T1 (de) |
| BR (1) | BR1100981A (de) |
| CA (1) | CA2109585C (de) |
| DE (1) | DE69231557T2 (de) |
| DK (1) | DK0588917T3 (de) |
| ES (1) | ES2153360T3 (de) |
| GR (1) | GR3035285T3 (de) |
| IE (1) | IE921690A1 (de) |
| PT (1) | PT100525B (de) |
| WO (1) | WO1992021339A1 (de) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08502508A (ja) * | 1992-10-23 | 1996-03-19 | メルク シヤープ エンド ドーム リミテツド | ドーパミンレセプターサブタイプリガンド |
| US5424444A (en) * | 1992-11-25 | 1995-06-13 | Abbott Laboratories | Method of preparing enantiomerically-pure 3-methyl-5-(1-alkyl-2(S)-pyrrolidinyl) isoxazoles |
| US5494680A (en) * | 1993-12-08 | 1996-02-27 | Minnesota Mining And Manufacturing Company | Transdermal delivery device |
| US5705512A (en) * | 1994-11-10 | 1998-01-06 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
| US5703100A (en) * | 1994-11-10 | 1997-12-30 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
| US5723477A (en) * | 1994-11-10 | 1998-03-03 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
| US5677459A (en) * | 1994-11-10 | 1997-10-14 | Sibia Neurosciences, Inc. | Methods for the preparation of modulators of acetylcholine receptors |
| US5594011A (en) * | 1994-11-10 | 1997-01-14 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
| US5824692A (en) * | 1995-01-06 | 1998-10-20 | Lippiello; Patrick Michael | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
| DE19501022C1 (de) * | 1995-01-14 | 1996-06-05 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System zur Verabreichung von (s)-3-Methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazol oder einem seiner pharmazeutisch akzeptablen Salze und Verfahren zu seiner Herstellung |
| WO1996030372A1 (fr) * | 1995-03-24 | 1996-10-03 | Japan Tobacco Inc. | Derives diazabicyclo[3.3.1]nonane et leurs intermediaires, leur application therapeutique et procedes de production |
| US6194581B1 (en) | 1995-04-07 | 2001-02-27 | Merck & Co., Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5583140A (en) * | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| US5794887A (en) | 1995-11-17 | 1998-08-18 | Komerath; Narayanan M. | Stagnation point vortex controller |
| US5723414A (en) * | 1996-01-24 | 1998-03-03 | Rohm And Haas Company | 5-aryl-isoxazolinones and herbicidal use thereof |
| JP4357001B2 (ja) | 1996-04-23 | 2009-11-04 | ターガセプト，インコーポレイテッド | 中枢神経系障害の予防及び治療のための医薬組成物 |
| US5706829A (en) * | 1996-06-06 | 1998-01-13 | Creighton University | Method for treating neurocardiogenic syncope |
| US5760049A (en) * | 1997-02-21 | 1998-06-02 | Synapse Pharmaceuticals International, Inc. | Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use |
| US6166032A (en) * | 1997-02-07 | 2000-12-26 | Synapse Pharmaceuticals International, Inc. | Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use |
| DK0984965T3 (da) * | 1997-05-30 | 2004-09-27 | Neurosearch As | 8-azabicyclo[3.2.1]oct-2-enderivater som cholinerge ligander ved nikotin-ACh-receptorer |
| NZ500644A (en) | 1997-05-30 | 2001-08-31 | Neurosearch As | Azacyclooctane and azacycloheptane derivatives useful as nicotinic ACh receptor modulators |
| DE69811070T2 (de) | 1997-05-30 | 2003-10-02 | Neurosearch A/S, Ballerup | 9-azabicyclo(3.3.1)non-2-ene und nonanderivate als liganden der nicotinergen rezeptoren |
| US7214686B2 (en) | 1997-06-30 | 2007-05-08 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
| US6133002A (en) | 1997-09-25 | 2000-10-17 | Dsm N.V. | Process for preparing optically active 2-amino-ω-oxoalkanoic acid derivatives |
| US6218383B1 (en) | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
| EP1274444B1 (de) * | 2000-03-16 | 2013-05-15 | THE McLEAN HOSPITAL CORPORATION | Cdp-cholin und uridin zur behandlung von alkoholmissbrauch |
| JP4667041B2 (ja) * | 2002-11-08 | 2011-04-06 | ザ マクレーン ホスピタル コーポレーション | タバコ依存症および離脱症状の治療用化合物 |
| JP4717444B2 (ja) * | 2002-12-20 | 2011-07-06 | ザ マクレーン ホスピタル コーポレーション | 睡眠／覚醒サイクルの正規化のための化合物 |
| US20050113449A1 (en) * | 2003-10-08 | 2005-05-26 | Renshaw Perry F. | Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications |
| US20050129710A1 (en) * | 2003-10-08 | 2005-06-16 | Renshaw Perry F. | Methods of treating psychiatric substance abuse, and other disorders using combinations containing omega-3 fatty acids |
| DE602004024565D1 (de) | 2003-10-15 | 2010-01-21 | Targacept Inc | Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems |
| FR2862647B1 (fr) * | 2003-11-25 | 2008-07-04 | Aventis Pharma Sa | Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant |
| US20090215714A1 (en) * | 2004-06-10 | 2009-08-27 | Perry Renshaw | Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder |
| WO2005122767A1 (en) * | 2004-06-10 | 2005-12-29 | Mclean Hospital Corporation | Pyrimidines, such as uridine, in treatments for patients with bipolar disorder |
| WO2006020703A1 (en) * | 2004-08-11 | 2006-02-23 | The Mclean Hospital Corporation | Compounds for the treatment of marihuana dependence, withdrawal, and usage |
| CA2580329C (en) | 2004-09-13 | 2015-01-06 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery |
| EP1977746B8 (de) | 2007-04-02 | 2014-09-24 | Parkinson's Institute | Verfahren und Zusammensetzung zur Verringerung der Nebenwirkungen von therapeutischen Behandlungen |
| US20100041621A1 (en) * | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods and compositions for improving cognitive performance |
| US8841329B2 (en) * | 2008-09-11 | 2014-09-23 | Dignity Health | Nicotinic attenuation of CNS inflammation and autoimmunity |
| WO2011085406A1 (en) | 2010-01-11 | 2011-07-14 | Mithridion, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| WO2012033956A1 (en) | 2010-09-08 | 2012-03-15 | Mithridion, Inc. | Cognition enhancing compounds and compositions, methods of making, and methods of treating |
| US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
| IL317757A (en) | 2013-02-28 | 2025-02-01 | Dermirainc | Glycopyrrolate salts |
| CA2974324A1 (en) | 2015-01-28 | 2016-08-04 | Zita S. Netzel | Drug delivery methods and systems |
| EP3565617A1 (de) | 2017-01-06 | 2019-11-13 | Chrono Therapeutics Inc. | Vorrichtungen und verfahren zur transdermalen wirkstofffreisetzung |
| JP7420797B2 (ja) | 2018-05-29 | 2024-01-23 | モーニングサイド ベンチャー インベストメンツ リミテッド | 薬剤送達の方法及びシステム |
-
1992
- 1992-05-28 EP EP92912971A patent/EP0588917B1/de not_active Expired - Lifetime
- 1992-05-28 WO PCT/US1992/004631 patent/WO1992021339A1/en active IP Right Grant
- 1992-05-28 CA CA002109585A patent/CA2109585C/en not_active Expired - Lifetime
- 1992-05-28 DK DK92912971T patent/DK0588917T3/da active
- 1992-05-28 DE DE69231557T patent/DE69231557T2/de not_active Expired - Lifetime
- 1992-05-28 ES ES92912971T patent/ES2153360T3/es not_active Expired - Lifetime
- 1992-05-28 PT PT100525A patent/PT100525B/pt active IP Right Grant
- 1992-05-28 JP JP50062493A patent/JP3153551B2/ja not_active Expired - Fee Related
- 1992-05-28 AT AT92912971T patent/ATE197454T1/de not_active IP Right Cessation
- 1992-07-01 IE IE169092A patent/IE921690A1/en not_active IP Right Cessation
-
1993
- 1993-09-08 US US08/118,079 patent/US5409946A/en not_active Expired - Lifetime
-
1997
- 1997-05-14 BR BR1100981-0A patent/BR1100981A/pt active IP Right Grant
-
2001
- 2001-01-24 GR GR20010400099T patent/GR3035285T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69231557D1 (de) | 2000-12-14 |
| EP0588917A4 (de) | 1994-04-13 |
| EP0588917A1 (de) | 1994-03-30 |
| WO1992021339A1 (en) | 1992-12-10 |
| PT100525B (pt) | 1999-10-29 |
| BR1100981A (pt) | 2000-04-18 |
| PT100525A (pt) | 1993-09-30 |
| JPH06508143A (ja) | 1994-09-14 |
| CA2109585A1 (en) | 1992-12-10 |
| US5409946A (en) | 1995-04-25 |
| CA2109585C (en) | 2000-02-15 |
| IE921690A1 (en) | 1992-12-02 |
| DE69231557T2 (de) | 2001-06-21 |
| DK0588917T3 (da) | 2001-02-12 |
| JP3153551B2 (ja) | 2001-04-09 |
| ES2153360T3 (es) | 2001-03-01 |
| GR3035285T3 (en) | 2001-04-30 |
| EP0588917B1 (de) | 2000-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69231557D1 (de) | Isoxazol- und isothiazolverbindungen, die die kognitiven funktionen verbesseren | |
| CA2136075A1 (en) | Heterocyclic ether compounds that enhance cognitive function | |
| DE602004020994D1 (de) | Piperidinverbindungen und pharmazeutische zusammensetzungen, die diese enthalten | |
| FI931888A0 (fi) | Kramploesande cykliska fruktopyranossulfiter -och sulfater | |
| KR950702829A (ko) | 신경계 퇴행성 질환의 치료에 유용한 아나바세인 유도체 | |
| TNSN99169A1 (fr) | Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| WO2003031435A8 (en) | Pyrazole derivatives as glycine transporter inhibitors | |
| HUT66971A (en) | 4-amino-naphthyridine derivatives pharmaceutical compositions containing the same and process for the production of thereof | |
| ATE170530T1 (de) | Thiazolidinderivate, ihre herstellung und medikamente, die sie enthalten | |
| PT1270570E (pt) | Composto de amida e sua utilizacao | |
| PT649846E (pt) | Derivados da galantamina processo para a sua preparacao e sua utilizacao como medicamentos | |
| EP0248086A4 (de) | Imidazolabkömmlinge, bakterizide, die diese enthalten und herstellungsverfahren. | |
| ATE140450T1 (de) | Neue n-benzoylprolin-derivate, verfahren zur herstellung und diese enthaltende arzneimittel | |
| MY132077A (en) | Use of n-substituted phenothiazines for the production of medicaments, novel substances and a process for their preparation | |
| ATE109142T1 (de) | 1-(pyridinylamino)-2-pyrrolidinone, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel. | |
| CA2450274A1 (en) | Benzoxazepine derivatives and their use as ampa receptor stimulators | |
| DE59408453D1 (de) | Pyrido-pyrimidindione, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel | |
| FR2355846A1 (fr) | Esters de penicillines utilisables comme medicaments | |
| SE8503109D0 (sv) | Cyclic prodrugs of antiinflammatory oxicams | |
| FR2413362A2 (fr) | Nouveaux antidotes de la famille des dichloracetamides | |
| ATE173734T1 (de) | Heteroarenylpiperazine, verfahren zu ihrer herstellung und ihre anwendung als medikamente | |
| ES8103082A1 (es) | Procedimiento de preparacion de nuevos derivados pirido (3,4-e)-as-triazinos acilados y de sus sales de acicion aci-da de los mismos | |
| GR3015592T3 (en) | Pharmaceuticals containing substituted cyclohex-2-en-1-yl-amine derivatives and their use in combatting diseases. | |
| TNSN99235A1 (fr) | Derives de 3 -azabicyclo [3,1,0] hexane nouveaux, procede pour leur preparation et compositions les contenant | |
| PL300155A1 (en) | Method of obtaining 3-amino pyroles non-substituted at their 1 position |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |